Phase 3 trial in advanced Colorectal Cancer shows that the addition of Vitamin C Intravenous used together with FOLFOX chemotherapy on the same 3 days was safe and well tolerated. It did not interfere and as a result should calm down fears on the use of this combination together with the FOLFOX chemotherapy protocol. In particular the data appeared to show a positive signal of increased survival in those with RAS Mutations (i.e. KRAS, NRAS) prompting recommendations by the authors to better research this population group that represents about 50% of patients with this cancer. Generally chemotherapy does not work well in this group and so the addition of vitamin C IV is encouraging to explore. As an aside greater than 90% pancreatic cancers as group can also have such RAS mutations which may explain the recent findings on the significant increase in survival when vitamin C was combined with chemotherapy (i.e. Gemcitabine and Abraxane).
